A major collaboration aims to expand access to immuno-oncology treatments as FYB206 moves toward FDA submission.
Mumbai, India, 10 December 2025 – Zydus Lifesciences has...
Ganaplacide lumefantrine combination delivers cure rates above WHO standards, offering new hope against growing artemisinin resistance.
London, 13 November 2025 – A major step forward...
Robust revenue expansion, higher profitability, strategic acquisitions, and new product launches position Zydus for a strong year ahead.
Sheridan, WY, 13 November 2025 – Zydus...
The global pharmaceutical industry, valued at a staggering $1.6 trillion, remains a cornerstone of global healthcare, yet it faces formidable production challenges. One of...
The evolution of gene therapy has transformed treatment possibilities for genetic disorders. Traditional strategies primarily target specific gene mutations by augmenting a defective gene...
